BiotechTube
Cristcot

Cristcot

Princeton, United States· Est.
cristcot.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Cristcot is a strategic pharmaceutical development company founded in 2008, headquartered in Austin, Texas. It has built a pipeline based on patented drug formulation and delivery platforms, with a lead Phase 3-ready asset for ulcerative colitis of the rectum. The company operates with an integrated model encompassing clinical research, device engineering, and regulatory strategy, positioning itself to address significant gaps in gastroenterology disease management.

Gastroenterology

Technology Platform

Patented drug formulation and unobtrusive drug-device combination delivery platforms focused on reliability, usability, and patient acceptance. IP covers compositions, devices, manufacturing, and assays.

Opportunities

The significant unmet need for patient-friendly, adherence-improving therapies in ulcerative colitis, particularly for distal disease, presents a clear market entry point.
Successful approval of the lead asset could validate the 'Unobtrusive Care' platform, enabling expansion into other gastroenterological conditions or therapeutic areas where drug delivery and patient experience are critical barriers.

Risk Factors

The company faces regulatory risk with its pending NDA submission and commercialization risk as a pre-revenue entity with no established sales force.
It also carries high concentration risk, as its near-term value is heavily dependent on the success of its single lead program in a competitive inflammatory bowel disease market.

Competitive Landscape

Cristcot competes in the crowded ulcerative colitis market against large pharma companies with systemic biologics and oral small molecules, as well as other localized therapies like enemas and suppositories. Its differentiation hinges on its patented drug-device combination designed for superior usability and patient acceptance compared to existing rectal delivery options.

More companies in Drug Delivery & Formulation →More companies in United States →